Inhibikase Therapeutics

Inhibikase Therapeutics, Inc. provides infectious disease treatments. It develops small molecule platform for treating both bacterial and viral infectious diseases. It operates through RAMP™ Drug Innovation Engine technology. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inhibikase Therapeutics advances trials amidst safety concerns and financial stability

Inhibikase Therapeutics made progress in trials but faces safety concerns and financial challenges.
Opportunities lie in advancing Phase III plans and clinical development for potential market growth.
The company's near-term milestones and financial stability are key areas to watch for future performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.

BOSTON and ATLANTA, Nov. 29, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced the publication of a paper describing the biochemical rationale and potential benefit of Abelson Tyrosine Kinase (c-Abl) inhibition as a potential disease-modifying therapy for Parkinson's Disease. The article, titled "Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity" was published online in the journal Movement Disorders on November 24, 2021 (DOI:  10/1002/mds.28858).

Inhibikase Therapeutics Announces Publication Highlighting Mechanism of Disease and the Potential of Oral c-Abl Kinase Inhibitor Therapy for the Treatment of Parkinson's Disease

BOSTON and ATLANTA, Nov. 15, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today reported financial results for the third quarter ended September 30, 2021 and highlighted recent developments. Key Business and Clinical Highlights Dosed first patient in the Phase 1b clinical trial of IkT-148009: In October 2021 Inhibikase dosed the first patient in its Phase 1b clinical trial of IkT-148009, a randomized, placebo-controlled trial to evaluate the safety, tolerability, and pharmacokinetics of IkT-148009.

Inhibikase Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity

ATLANTA, Oct. 19, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced dosing of the first Parkinson's patient in its Phase 1b clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson's disease. The Phase 1b extension study is a 3:1 randomized, placebo-controlled trial investigating the safety, tolerability and pharmacokinetics of IkT-148009.

Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009

The stock price of Inhibikase Therapeutics, Inc. (Nasdaq: IKT) increased over 5% pre-market today. This is why it happened.

IKT Stock: Why It Increased Today

ATLANTA, Oct. 4, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced interim three-month results from its ongoing chronic toxicology studies of oral IkT-148009 administered in rats and non-human primates (NHPs). The Company's ongoing toxicology studies of IkT-148009 are designed to meet the regulatory requirements for chronic dosing in humans, which include daily oral administration in rats for six months and in NHPs for nine months.

Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson's Disease

ATLANTA, Sept. 23, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that the Company has been awarded a $385,388 research grant from the U.S. National Institute of Neurological Disease and Stroke (NINDS), an Institute of the National Institutes of Health (NIH), to evaluate the therapeutic potential of IkT-148009, the Company's lead c-Abl inhibitor,  in a novel preclinical model for Multiple System Atrophy (MSA).

Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy

ATLANTA, Sept. 7, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced that Dr. Milton Werner, Ph.D.

Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference

ATLANTA, Aug. 16, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today reported financial results for the second quarter ended June 30, 2021 and highlighted recent developments. Key Business and Clinical Highlights Begin evaluation of IkT-148009 in Parkinson's patients: Following a teleconference on July 22, 2021with the U.S. Food and Drug Administration (FDA), Inhibikase and the FDA agreed that the Company may begin a Phase 1b extension study to evaluate the safety, tolerability and pharmacokinetics of the Company's lead drug candidate IkT-148009 in Parkinson's patients.

Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity

ATLANTA, July 26, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that, after a review of safety, tolerability and pharmacokinetic data from the Company's Phase 1 clinical trial of IkT-148009 in healthy volunteers, the United States Food and Drug Administration (FDA) has given the Company clearance to begin a Phase 1b extension study to evaluate its lead drug candidate IkT-148009 in Parkinson's patients. The randomized Phase 1 study investigated the safety, tolerability and pharmacokinetics (PK) of IkT-148009 in healthy volunteers aged 45 to 70 years old, with the objective of evaluating the safety, tolerability and the PK profile of IkT-148009 in single and multiple ascending dose settings.

Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients

ATLANTA, June 18, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced the closing of its previously announced underwritten public offering of 15 million shares of its common stock at a price to the public of $3.00 per share. The gross proceeds to Inhibikase from the public offering, before deducting underwriting discounts and commissions and offering expenses payable by Inhibikase, were $45 million.

Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock

Kindred Biosciences

Aprea Therapeutics

Catabasis Pharmaceuticals

Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and Inhibikase Therapeutics, Inc. (NASDAQ: IKT) are among the biggest biopharma movers on Wednesday. Kindred Flies On Buyout: Kindred announced an agreement to be bought by Elanco Animal Health Incorporated (NYSE: ELAN) for $9.25 per share, or approximately $440 million.

Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today

Inhibikase Therapeutics Inc (NASDAQ: IKT) has priced an underwritten public offering of 15 million shares at $3/share for gross proceeds of approximately $45 million. The offer price represents a 26% discount on the last close price of $4.03 on Tuesday.

Inhibikase Therapeutics Stock Drops After Follow-On Equity Offering Of $45M Issued At 26% Discount

The stock price of Inhibikase Therapeutics Inc (NASDAQ: IKT) fell by over 25% pre-market. This is why it happened.

IKT Stock Price Falls Over 25% Pre-Market: Why It Happened

ATLANTA, June 15, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced the pricing of an underwritten public offering of 15 million shares of its common stock at a public offering price of $3.00 per share for total gross proceeds of approximately $45 million (the "Offering) before deducting underwriting discounts and commissions and offering expenses payable by Inhibikase. In addition, Inhibikase has granted the underwriters a 45-day option to purchase up to 2.25 million additional shares of common stock at the public offering price, less underwriting discounts and commissions.

Inhibikase Therapeutics Prices Follow-On Public Offering of Common Stock

ATLANTA, May 25, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced that Dr. Milton Werner, Ph.D., Chief Executive Officer of Inhibikase, will present at the Jefferies Virtual Healthcare Conference: Jefferies Virtual Healthcare Conference Date: Tuesday, June 1, 2021Time: 3:30pm ET The Company also announced a presentation by Dr. Werner at the LD Micro Virtual Invitational XI: LD Micro Virtual Invitational  XI Date: Thursday, June 10, 2021Time: 11:30am ET Dr. Werner will present and discuss the clinical pharmacokinetics and adverse event profile of IkT-148009, the Company's lead asset being developed for the treatment of Parkinson's disease in the brain and gastrointestinal tract.

Inhibikase Therapeutics to Present at Upcoming Jefferies Virtual Healthcare Conference & Others

ATLANTA, May 17, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today reported financial results for the first quarter ended March 31, 2021 and highlighted recent developments. Key Business and Clinical Highlights Accelerated timelines for Phase 1 Study of IkT-148009 for the treatment of PD and associated GI Disorders: In February, 2021 Inhibikase commenced patient dosing in its Phase 1 study evaluating the safety, tolerability and pharmacokinetics of IkT-148009, the Company's novel brain penetrant Abelson tyrosine kinase (c-Abl) inhibitor with the potential to modify Parkinson's disease and its gastrointestinal complications.

Inhibikase Therapeutics Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity

ATLANTA, April 21, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders inside and outside of the brain, today announced that Milton Werner, Ph.D., President and Chief Executive Officer, will provide an update on clinical measures of dosing pharmacokinetics and elaborate on IKT-148009's mechanism of action at the Sachs 4th Annual Neuroscience Innovation Forum being held virtually on April 28-30, 2021.

Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum

ATLANTA, April 1, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease (PD) and related disorders inside and outside of the brain, today reported financial results for the fourth quarter and full year ended December 31, 2020 and highlighted recent developments. Key Business and Clinical Highlights Completed Initial Public Offering: In December 2020, Inhibikase successfully completed its initial public offering (IPO) of 1,800,000 shares of common stock at a public offering price of $10.00 per share.

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity

ATLANTA, Feb. 22, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders, today announced that it will present findings from its oral therapy studies for...

Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) Conference

ATLANTA--(BUSINESS WIRE)--Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced dosing of the first patients in its Phase 1 clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson's disease. This randomized Phase 1 study is investigating the safety, tolerability and pharmacokinetics (PK) of IkT

Inhibikase Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson's Disease and Related Disorders

ATLANTA, Jan. 4, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders, announced today that it has formed a partnership with Clintrex Research...

Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical Officer

ATLANTA, Dec. 28, 2020 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase"), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders that arise inside and outside of the brain, announced today the closing of its...

Inhibikase Therapeutics Announces Closing of Initial Public Offering

GBS and Inhibikase Therapeutics priced late Tuesday.

News for Inhibikase Therapeutics Stock (IKT)